Author

Eric R. Hantz

University of California, San FranciscoORCID 0000-0002-2588-7619Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Biophysics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Approach:benchmark study· 1 Research Focus:benchmarking· 1 Approach:deep learning· 1 Approach:diffusion model· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Adam R. RensloiD· 3 shared Brian K. ShoichetiD· 3 shared G.J. CorreyiD· 3 shared Nevan J. KroganiD· 3 shared Alan AshworthiD· 2 shared James S. FraseriD· 2 shared Julia RosecransiD· 2 shared Maisie GV StevensiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiophysics

Adam R. RensloORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BiophysicseLifePeer-reviewedOct 12, 2026

✦ In-depth digest

Large scale prospective evaluation of co-folding across hundreds of Mac1-ligand complexes and three virtual screens

Jongbin Kim, G.J. Correy, Brendan W. Hall…·James S. Fraser

On 489 evaluable new Mac1 complexes, AlphaFold3, Chai-1 and Boltz-2 placed over half of ligands within 2 Å, but on docking hit-lists AF3 and Boltz-2 added little over docking.

7 citationstop 1%

virusprotein structure

𝕏 PostBluesky

Pharmacology & ToxicologyJournal of Medicinal ChemistryPeer-reviewedDec 17, 2025

Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy in vivo

Priyadarshini Jaishankar, G.J. Correy, Yusuke Matsui…·Adam R. Renslo

This paper identifies AVI-6451, an orally bioavailable inhibitor of SARS-CoV-2 Mac1 with once-daily efficacy in a mouse model.

6 citationstop 4%

mouseexperimental assay

𝕏 PostBluesky

BiochemistryScience AdvancesPeer-reviewedApr 23, 2025

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-MPro inhibitors with potent in vivo efficacy

Tyler C. Detomasi, Gilles Degotte, Sijie Huang…·Charles S. Craik

This paper describes the discovery of new coronavirus MPro inhibitors with improved pharmacokinetics, broad-spectrum antiviral activity, and superior in vivo efficacy compared to existing drugs.

16 citationstop 1%

humanproteomics

𝕏 PostBluesky